BCAL Diagnostics (ASX:BDX) Receivables Turnover : 0.00 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is BCAL Diagnostics Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. BCAL Diagnostics's Revenue for the six months ended in Dec. 2023 was A$0.00 Mil. BCAL Diagnostics's average Accounts Receivable for the six months ended in Dec. 2023 was A$0.01 Mil.

BCAL Diagnostics Receivables Turnover Historical Data

The historical data trend for BCAL Diagnostics's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BCAL Diagnostics Receivables Turnover Chart

BCAL Diagnostics Annual Data

Trend

Jun22

Jun23

Receivables Turnover

BCAL Diagnostics Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
Receivables Turnover	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of BCAL Diagnostics's Receivables Turnover

For the Diagnostics & Research subindustry, BCAL Diagnostics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BCAL Diagnostics's Receivables Turnover Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, BCAL Diagnostics's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where BCAL Diagnostics's Receivables Turnover falls into.

BCAL Diagnostics Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

BCAL Diagnostics's Receivables Turnover for the fiscal year that ended in Jun. 2023 is calculated as

	Receivables Turnover (A: Jun. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Jun. 2023 )	/ (	(Accounts Receivable (A: Jun. 2022 )	+	Accounts Receivable (A: Jun. 2023 ))	/	count )
=	0	/ (	(0	+	0)	/	1 )
=	0	/	0
=	N/A

BCAL Diagnostics's Receivables Turnover for the quarter that ended in Dec. 2023 is calculated as

	Receivables Turnover (Q: Dec. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Dec. 2023 )	/ (	(Accounts Receivable (Q: Jun. 2023 )	+	Accounts Receivable (Q: Dec. 2023 ))	/	count )
=	0	/ (	(0	+	0.007)	/	1 )
=	0	/	0.007
=	N/A

BCAL Diagnostics (ASX:BDX) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

BCAL Diagnostics Receivables Turnover Related Terms

Thank you for viewing the detailed overview of BCAL Diagnostics's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

BCAL Diagnostics (ASX:BDX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BCAL Diagnostics Ltd (ASX:BDX) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

N/A

Address

Queen Victoria Building, GPO Box Q128, Sydney, NSW, AUS, 1230

Website

https://www.bcaldiagnostics.com

BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer by identifying, measuring, and validating specific biomarkers enriched from patient's blood. The BCAL technology utilizes a single blood test on multiple levels including disease detection, diagnostic mass screening, and post-intervention.